Supplementary Material

Article Title: Effects of Adjunctive Metformin on Metabolic Traits in Nondiabetic Clozapine-Treated Patients With Schizophrenia and the Effect of Metformin Discontinuation on Body Weight: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study

Author(s): Chun-Hsin Chen, MD; Ming-Chyi Huang, MD, PhD; Chung-Feng Kao, PhD; Shih-Ku Lin, MD; Po-Hsiu Kuo, PhD; Chih-Chiang Chiu, MD, PhD; and Mong-Liang Lu, MD

List of Supplementary Material for the article

1. **Supplementary eTable 1**   Difference test between baseline and follow-up (paired *t*-test) and difference test within group over time (one-way within-subjects ANOVA)

Disclaimer
This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Tables

Table S1. Difference test between baseline and follow-up (paired t-test) and difference test within group over time (one-way within subjects ANOVA)

Metabolic related traits	Group	Mean difference (s.d.)[a]					p-value[b]
		Baseline vs. 2-week	Baseline vs. 4-week	Baseline vs. 8-week	Baseline vs. 16-week	Baseline vs. 24-week	Within group (df=5)
BW	Metformin	-0.7 (1.9)	**-1.1 (2.1)**[*]	**-1.3 (2.2)**[**]	**-2.2 (2.9)**[***]	**-3.2 (3.1)**[***]	**<0.0001**
	Placebo	-0.3 (1.2)	-0.2 (1.4)	0.2 (1.8)	-0.1 (1.8)	-0.2 (2.1)	0.72
BMI	Metformin	-0.2 (0.7)	**-0.4 (0.7)**[**]	**-0.5 (0.8)**[**]	**-0.8 (1.0)**[***]	**-1.2 (1.1)**[***]	**<0.0001**
	Placebo	-0.1 (0.4)	-0.1 (0.5)	0.1 (0.7)	0.0 (0.7)	0.0 (0.7)	0.52
WC	Metformin	**-1.7 (4.0)**[*]	**-2.2 (4.6)**[*]	**-2.2 (4.6)**[*]	-1.2 (7.9)	-1.5 (10.3)	0.40
	Placebo	-0.3 (2.2)	-0.3 (3.2)	-0.6 (2.8)	-0.4 (3.6)	0.3 (4.5)	0.46
SBP	Metformin	**7.4 (10.3)**[***]	5.2 (16.9)	1.7 (11.8)	-2.0 (22.3)	-0.8 (23.5)	0.056
	Placebo	-0.6 (15.2)	3.5 (15.9)	1.8 (12.3)	-0.3 (12.7)	-0.7 (18.1)	0.61
DBP	Metformin	2.4 (11.5)	1.4 (13.6)	-0.9 (12.5)	-0.8 (14.1)	-2.8 (14.6)	0.25
	Placebo	2.4 (13.2)	3.2 (10.3)	2.0 (10.7)	-0.2 (10.2)	0.8 (13.1)	0.48
FPG	Metformin	**-7.4 (11.7)**[**]	**-6.0 (15.4)**[*]	**-9.7 (15.5)**[**]	**-13.1 (12.4)**[***]	**-8.7 (16.6)**[*]	**<0.0001**
	Placebo	**5.1 (9.6)**[*]	4.6 (16.8)	-0.5 (20.9)	-1.5 (16.8)	5.7 (17.6)	**0.02**
TG	Metformin	**-18.8 (45.7)**[*]	-19.8 (64.2)	**-26.7 (52.2)**[*]	-16.5 (55.8)	-20.5 (53.8)	0.11
	Placebo	8.3 (72.3)	15.5 (55.7)	8.2 (84.9)	8.0 (128.2)	4.4 (46.0)	0.94
HDL-C	Metformin	-1.9 (6.4)	-1.1 (7.2)	**-3.3 (6.9)**[*]	**-3.1 (7.5)**[*]	**-3.3 (7.7)**[*]	**0.03**
	Placebo	1.0 (6.3)	-0.8 (7.3)	-0.9 (5.2)	-2.2 (9.6)	-0.6 (5.5)	**0.03**
Insulin	Metformin	**-1.5 (3.4)**[*]	-1.6 (6.3)	**-3.2 (5.0)**[**]	**-3.7 (5.1)**[***]	-1.8 (6.4)	**0.01**
	Placebo	0.6 (5.9)	2.3 (6.4)	0.7 (5.7)	0.5 (5.4)	4.4 (12.7)	0.07

HOMA-IR	Metformin	**-0.6 (1.0)**[*]	-0.6 (1.9)	**-1.0 (1.5)**[**]	**-1.2 (1.6)**[***]	-0.6 (2.0)	**0.02**
	Placebo	0.4 (1.7)	0.8 (2.0)	0.3 (1.7)	0.2 (1.5)	1.5 (3.9)	0.06

[a] Mean difference represents the mean of baseline subtract the mean of follow-up. Difference tests between baseline and follow-up in the metformin group and the placebo group used paired *t*-test. Values in bold represent significant (i.e. *p*<0.05) difference between baseline and follow-up in groups.

[b] Difference tests within group are based on 28 subjects in the metformin group and based on 27 subjects in the placebo group using one-way within subjects ANOVA with df=5.

[*]*p*<0.05, [**]*p*<0.01, [***]*p*<0.001.

Abbreviations: BMI = body mass index, BW = body weight, DBP = diastolic blood pressure, FPG = fasting plasma glucose, HDL-C = high density lipoprotein cholesterol, HOMA-IR = homeostasis model assessment-insulin resistance, SBP = systolic blood pressure, TG = triglyceride, WC = waist circumference.